| Company Name: |
ShangHai Onsyn-Chemical Technology Co., Ltd.
|
| Tel: |
13917628136 15900795984 |
| Email: |
572350448@qq.com |
| Products Intro: |
Product Name:4-{8-[(2,6-diethoxy-4'-fluorobiphenyI-4-yl)Methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid CAS:1254730-81-8 Purity:98% Package:10Mg, 100Mg, 10g
|
|
| | MK-5582 Basic information |
| Product Name: | MK-5582 | | Synonyms: | MK-5582;4-(8-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)Methyl)-3-oxo-2,8-diazaspiro[4.5]decan-2-yl)benzoic acid;4-{8-[(2,6-diethoxy-4'-fluorobiphenyI-4-yl)Methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid;SSTR5 antagonist 2;Benzoic acid, 4-[8-[(2,6-diethoxy-4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl]-;SSTR5 antagonist 2,SSTR-5 antagonist 2;4-[8-({2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl}methyl)-3-oxo-2,8-diazaspiro[4.5]decan-2-yl]benzoic acid;4-(8-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-3-oxo-2,8-diazaspiro[4.5]dec-2-yl)benzoic acid | | CAS: | 1254730-81-8 | | MF: | C32H35FN2O5 | | MW: | 546.63 | | EINECS: | | | Product Categories: | | | Mol File: | 1254730-81-8.mol |  |
| | MK-5582 Chemical Properties |
| Boiling point | 710.2±60.0 °C(Predicted) | | density | 1.30±0.1 g/cm3(Predicted) | | pka | 4.34±0.10(Predicted) |
| | MK-5582 Usage And Synthesis |
| Uses | SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM)[1]. | | in vivo | SSTR5 antagonist 2 (10 mg/kg, orally) increases both total and active circulating incretin hormone GLP1 levels in mice at a dose of 10 mg/kg[1]. SSTR5 antagonist 2 increases pancreatic insulin secretion as well as total and active GLP1 release, and demonstrates synergistic effects in combination with DPP4 inhibitors[1]. | Animal Model: | Rodent diabetic model without risk of hypoglycemia[1]. | | Dosage: | 10 mg/kg. | | Administration: | Orally. | | Result: | Increased both total and active circulating incretin hormone GLP1 levels. |
| | References | [1] Liu W, et al. Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition. ACS Med Chem Lett. 2018 Sep 12;9(11):1082-1087. DOI:10.1021/acsmedchemlett.8b00305 |
| | MK-5582 Preparation Products And Raw materials |
|